<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661011</url>
  </required_header>
  <id_info>
    <org_study_id>ELCWP 01061</org_study_id>
    <nct_id>NCT00661011</nct_id>
  </id_info>
  <brief_title>Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy</brief_title>
  <official_title>A Phase II Study Assessing the Curative Effect of the Combination of Lobectomy Followed by Mediastinal Concomitant Radiochemotherapy in Patients With Locally Advanced Unresectable Stage III Non-small Cell Lung Cancer Responding to Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if radical radiochemotherapy on the mediastinum
      after lobectomy can be associated with significant long term survival in patients with
      initially unresectable stage III NSCLC responding to induction chemotherapy but in which the
      residual disease is too large to be treated by radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to too slow recruitment
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Survival will be dated from the day of registration until death or last follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative mortality and morbidity</measure>
    <time_frame>To be observed during the 30 days following the surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>After completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>After each course of chemotherapy and at the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Non Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobectomy followed by mediastinal concomitant chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lobectomy followed by concomitant mediastinal chemoradiotherapy</intervention_name>
    <description>Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of non-small cell carcinoma of the lung

          -  Initially stage III NSCLC

          -  Pathologically proven N2 or N3 disease

          -  Any response to induction chemotherapy (whatever the regimen administered)

          -  Disease still not fully resectable (because of extensive mediastinal N disease) and
             not suitable for radical radiotherapy (single field) after induction chemotherapy

          -  Lobectomy possible for the treatment of T disease

          -  Availability for participating in the detailed follow-up of the protocol

          -  Informed consent

        Exclusion Criteria:

          -  Prior treatment with radiotherapy or surgery

          -  Karnofsky PS &lt; 60

          -  Functional or anatomical contra-indication to mediastinal radiotherapy

          -  Functional or anatomical contra-indication to surgical lobectomy

          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free
             interval)

          -  Malignant pleural or pericardial effusion

          -  Neutrophils &lt; 2,000/mm³

          -  Platelet cells &lt; 100,000/mm3

          -  Serum bilirubin &gt; 1.5 mg/100 ml

          -  Serum creatinine &gt; 1.5 mg/100 ml and/or creatinine clearance &lt; 60 ml/min

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure or cardiac arrhythmia requiring medical treatment

          -  Uncontrolled infectious disease

          -  Hearing loss

          -  Symptomatic polyneuropathy

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Sculier, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>European Lung Cancer Working Party</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pneumology RHMS Hôpital de la Madeleine</name>
      <address>
        <city>Ath</city>
        <zip>7800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHR St Joseph-Warquignies</name>
      <address>
        <city>Boussu</city>
        <zip>7360</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Hospital Ixelles-Molière</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Hôpital Saint-Joseph</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Vésale - Montigny-le-Tilleul</name>
      <address>
        <city>Montigny-le-Tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Centre Hospitalier de Mouscron</name>
      <address>
        <city>Mouscron</city>
        <zip>7700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology St Savas Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hospital de Sagunto</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Concomitant radiochemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Unresectable stage III non-small cell lung carcinoma</keyword>
  <keyword>Surgery</keyword>
  <keyword>Unresectable stage III non-small cell lung carcinoma not suitable for radical radiotherapy after objective response to induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

